Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Merck KGaA
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
An open-label, multicenter, multinational Phase III follow-up study to investigate the long-term safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia
To demonstrate the long-term safety of Sarizotan HCl 1 mg b.i.d. administered to Parkinson patients with dyskinesia.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
MMerck KGaA
Update Il y a 4 ans
A randomized, double-blind, controlled phase III study of Stimuvax® (L-BLP25 or BLP25 liposome vaccine) in combination with hormonal treatment versus hormonal treatment alone for first-line therapy of post-menopausal women with estrogen receptor (ER)-positive and/or progesterone receptor (PgR)-positive, inoperable locally advanced, recurrent, or metastatic breast cancer STRIDE - STimulating immune Response In aDvanced brEast cancer
PrimaryDemonstration of superior efficacy (as measured by PFS time) of L-BLP25 in combination with hormonal treatment (HT) over placebo plus HT, when used for first-line therapy of hormone receptor-po...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
Abituzumab in SSc-ILD
The primary objective of the trial is to demonstrate efficacy of abituzumab in improving lung function of subjects with SSc-ILD.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
Efficacy and safety study of atacicept in patients with Systemic Lupus Erythematosus (ADDRESS II)
Primary: 1. Evaluate the efficacy of atacicept compared to placebo in reducing SLE disease activity in subjects treated with standard of care (SoC) therapy and to investigate the dose-response relati...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX-4 plus cetuximab versus UFOX plus cetuximab as first-line therapy in subjects with metastatic colorectal cancer
The primary objective of this study is to compare the PFS in subjects receiving cetuximab plus either UFOX or FOLFOX-4 as initial treatment for metastatic colorectal cancer.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
Avelumab in Third-Line Gastric Cancer
The primary objective is to demonstrate superiority with regard to overall survival (OS) of avelumab plus best supportive care (BSC) versus physician’s choice (chosen from a pre-specified list of ther...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
START – Stimulating Targeted Antigenic Responses To NSCLC A multi-center phase III randomized, double-blind placebo-controlled study of the cancer vaccine Stimuvax® (L-BLP25 or BLP25 liposome vaccine) in non-small cell lung cancer (NSCLC) subjects with unresectable stage III disease
Primary objective: · To compare survival duration of all randomized subjects by treatment arm.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
MSB11022 in moderately to severely active rheumatoid arthritis
The primary objective of this study is to evaluate the safety profile of MSB11022 compared to reference product in patients with moderately to severely active rheumatoid arthritis (RA) up to Week 52.
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Merck KGaA
Update Il y a 4 ans
Randomized Phase II trial with cetuximab and cisplatin in the treatment of ER negative, PgR negative, HER2 negative metastatic breast carcinoma (“basal-like”)
To assess overall response to cetuximab in combination with cisplatin and to show the superiority of the combination over cisplatin alone, in subjects with “triple negative” metastatic breast cancer.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Serono Int, a branch of Laboratoires Serono SA an affiliate of Merck KGaA, Darmstadt, Germany
Update Il y a 4 ans
A randomised, double-blind, placebo-controlled, multicentre, Phase II dose-finding study of atacicept given subcutaneously in subjects with rheumatoid arthritis and inadequate response to TNFa antagonist therapy
To evaluate the efficacy of three dose levels of atacicept in the treatment of signs and symptoms of subjects with active rheumatoid arthritis (RA) who have had an inadequate response to previous TNFa...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
Next